Distinct modes of interaction within eIF4F-like complexes and susceptibility to the RocA inhibitor for the

Danielle M N Moura1, Amanda L Soares1, Adalúcia da Silva1

  • 1Aggeu Magalhães Institute, Oswaldo Cruz Foundation (Fiocruz), Recife, Pernambuco, Brazil.

Plos One
|May 9, 2025
PubMed

Insights

Investigating the EIF4AI protein in Trypanosoma brucei reveals its specific interactions and function in mRNA translation. While Rocaglamide A inhibits mammalian eIF4A, it shows limited efficacy against T. brucei due to a key amino acid difference.

Area of Science:

  • Molecular Biology
  • Parasitology
  • Biochemistry

Background:

  • Trypanosomatids cause significant human diseases and possess unique gene expression mechanisms.
  • mRNA translation in these parasites involves multiple eIF4F-like complexes, crucial for ribosome binding.
  • Eukaryotic translation initiation factor 4A (eIF4A) is vital for eIF4F complex function and a potential drug target.

Purpose of the Study:

  • To elucidate the function of EIF4AI, the sole eIF4A homologue in trypanosomatids.
  • To identify EIF4AI's interacting partners and its role in mRNA translation.
  • To assess the potential of eIF4A inhibitors, like Rocaglamide A, for treating trypanosomatid infections.

Main Methods:

  • Interactome analysis of wild-type and mutant EIF4AI in Trypanosoma brucei.
  • Fluorescent-based tethering assays to evaluate mRNA expression.
  • Assessment of parasite susceptibility to Rocaglamide A in T. brucei and Leishmania infantum.

Main Results:

  • Wild-type EIF4AI strongly interacts with the eIF4E4/eIF4G3 complex, while a mutant EIF4AI (DEAD/DQAD) interacts with eIF4E3/eIF4G4.
  • EIF4AI, but not the mutant, stimulates mRNA expression, and this stimulation is blocked by Rocaglamide A.
  • T. brucei and L. infantum show reduced susceptibility to Rocaglamide A compared to mammalian cells, linked to an amino acid substitution in T. brucei EIF4AI's RocA binding pocket.

Conclusions:

  • EIF4AI plays a specific role in trypanosomatid mRNA translation.
  • The structural difference in T. brucei EIF4AI impairs Rocaglamide A binding, explaining its limited efficacy.
  • These findings provide a basis for developing targeted EIF4AI inhibitors for trypanosomatid diseases.